

Viral Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/V5623C970D4FEN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: V5623C970D4FEN

Abstracts

The 7 major viral hepatitis markets are expected to exhibit a CAGR of 2.69% during 2024-2034.

The viral hepatitis market has been comprehensively analyzed in IMARC's new report titled "Viral Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Viral hepatitis refers to a group of infectious diseases that primarily affect the liver and are caused by different viruses, including hepatitis A, B, C, D, and E. These viruses can result in inflammation and damage to the liver, leading to a range of symptoms and potential long-term complications. Some of the common indications are fatigue, loss of appetite, nausea, vomiting, abdominal pain, jaundice, etc. Many patients may also experience dark urine, pale stools, muscle and joint aches, a general feeling of unwellness, etc. Chronic hepatitis may not cause noticeable symptoms initially but can lead to long-term liver damage, cirrhosis, and an increased risk of liver cancer. The diagnosis of viral hepatitis involves a combination of clinical evaluation, laboratory tests, and medical history assessment. Blood tests are essential for detecting specific viral markers, including antibodies, antigens, viral genetic material, etc. Various imaging modalities, such as ultrasound, CT scans, MRI, etc., may be used to assess liver health and detect any complications. Additionally, liver biopsy or non-invasive methods, including elastography and serum biomarkers, may be performed to evaluate liver fibrosis or monitor disease progression.

The increasing cases of ingesting contaminated food or water, coupled with the growing prevalence of poor sanitation and inadequate hygiene practices, are primarily driving the viral hepatitis market. In addition to this, the rising incidence of exposure to infected blood or other body fluids through the sharing of contaminated needles or syringes,

sexual contact, mother-to-child transmission during childbirth, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of antiviral medications, such as nucleotide analogs and interferon-alpha, for suppressing viral replication and preventing complications associated with the ailment is further bolstering the market growth. Apart from this, the inflating application of liver-supportive drugs, including hepatoprotective agents like milk thistle extract, to improve liver health, enhance liver cell regeneration, and minimize inflammation is acting as another significant growth-inducing factor. Additionally, the emerging popularity of nucleic acid testing (NAT), since it allows the direct detection and quantification of viral RNA or DNA in blood samples and is particularly useful in diagnosing acute hepatitis, determining viral load, and assessing disease progression, is expected to drive the viral hepatitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the viral hepatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for viral hepatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the viral hepatitis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the viral hepatitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the viral hepatitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current viral hepatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the viral hepatitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the viral hepatitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the viral hepatitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of viral hepatitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of viral hepatitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of viral hepatitis by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of viral hepatitis by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with viral hepatitis across the seven major markets?

What is the size of the viral hepatitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of viral hepatitis?

What will be the growth rate of patients across the seven major markets?

Viral Hepatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for viral hepatitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the viral hepatitis market?

What are the key regulatory events related to the viral hepatitis market?

What is the structure of clinical trial landscape by status related to the viral hepatitis market?

What is the structure of clinical trial landscape by phase related to the viral hepatitis market?

What is the structure of clinical trial landscape by route of administration related to the viral hepatitis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 VIRAL HEPATITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 VIRAL HEPATITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 VIRAL HEPATITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)
 - 7.7.4 Epidemiology by Gender (?2018-2034?)
 - 7.7.5 Epidemiology by Type (?2018-2034?)
 - 7.7.6 Diagnosed Cases (?2018-2034?)
 - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Epidemiology by Type (?2018-2034?)
 - 7.8.6 Diagnosed Cases (?2018-2034?)
 - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Epidemiology by Type (?2018-2034?)
 - 7.9.6 Diagnosed Cases (?2018-2034?)
 - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 VIRAL HEPATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 VIRAL HEPATITIS - UNMET NEEDS

10 VIRAL HEPATITIS - KEY ENDPOINTS OF TREATMENT

11 VIRAL HEPATITIS - MARKETED PRODUCTS

- 11.1 List of Viral Hepatitis Marketed Drugs Across the Top 7 Markets

- 11.1.1 Hepsera (Adefovir dipivoxil) - Gilead Sciences
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) - Gilead Sciences
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Sovaldi (Sofosbuvir) - Gilead Sciences
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Zepatier (Elbasvir/ Grazoprevir) - Merck and Co
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Harvoni (Ledipasvir/sofosbuvir) - Gilead Sciences
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 VIRAL HEPATITIS - PIPELINE DRUGS

- 12.1 List of Viral Hepatitis Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Peginterferon Lambda-1a - Eiger BioPharmaceuticals
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. VIRAL HEPATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. VIRAL HEPATITIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 VIRAL HEPATITIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Viral Hepatitis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Viral Hepatitis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Viral Hepatitis - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Viral Hepatitis - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Viral Hepatitis - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Viral Hepatitis - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Viral Hepatitis - Market Size by Therapies

- 15.4.2.1 Market Size by Therapies (2018-2023)
- 15.4.2.2 Market Forecast by Therapies (2024-2034)
- 15.4.3 Viral Hepatitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Viral Hepatitis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Viral Hepatitis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Viral Hepatitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Viral Hepatitis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Viral Hepatitis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Viral Hepatitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Viral Hepatitis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Viral Hepatitis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Viral Hepatitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Viral Hepatitis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Viral Hepatitis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Viral Hepatitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Viral Hepatitis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)

15.9.2 Viral Hepatitis - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Viral Hepatitis - Access and Reimbursement Overview

16 VIRAL HEPATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 VIRAL HEPATITIS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 VIRAL HEPATITIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Viral Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/V5623C970D4FEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V5623C970D4FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

